To identify, clone ,sequence and highly express the mature peptide gene of ApoA Ⅰ, total RNA was prepared from human fetal liver tissue. cDNA fragment encoding human ApoA Ⅰ was amplified by RT-PCR using specific pri...To identify, clone ,sequence and highly express the mature peptide gene of ApoA Ⅰ, total RNA was prepared from human fetal liver tissue. cDNA fragment encoding human ApoA Ⅰ was amplified by RT-PCR using specific primers, and then was inserted in pGEM-T vector. DNA sequencing indicates that the fragment is 729 base pairs in length and has 100% nucleotide homology with that of reported ApoA Ⅰ cDNA gene previously. The ApoA Ⅰ gene was cloned into pGEX 5X-1.The recombinant protein was expressed in E.coli DH5α, purified by glutathione-Sepharose 4B affinity chromatography and confirmed by SDS-PAGE. It was shown that the recombinant ApoA Ⅰ was expressed in E.coli, and the target protein amounted to 36% of total bacteria proteins. Cholesteryl ester transfer experiment showed that the recombinant ApoA Ⅰ was capable of promoting transfer of CE from HDL to LDL. Western blotting showed that the protein could react specifically with anti-ApoA Ⅰ antibodies.展开更多
目的探讨载脂蛋白A-Ⅰ模拟肽(L-4F)对肥胖大鼠心功能的影响及可能机制。方法 50只SD大鼠中,随机选择10只喂食普通饲料为对照组,另40只喂食高脂饲料8周后,肥胖模型造模成功率75%,将肥胖模型成功大鼠30只再随机分为肥胖组、诱导剂组[血红...目的探讨载脂蛋白A-Ⅰ模拟肽(L-4F)对肥胖大鼠心功能的影响及可能机制。方法 50只SD大鼠中,随机选择10只喂食普通饲料为对照组,另40只喂食高脂饲料8周后,肥胖模型造模成功率75%,将肥胖模型成功大鼠30只再随机分为肥胖组、诱导剂组[血红素氧合酶1(HO-1)诱导剂L-4F]和抑制剂组(HO-1抑制剂SnMP),每组10只,各组每天腹腔注射相应药物,持续8周。心脏超声和血流动力学检测后,自腹主动脉取血,ELISA检测各项指标。苏木精-伊红染色观察心肌组织病理变化;分别用RT-PCR和Western blot测心肌组织HO-1、脂联素基因和蛋白表达。结果与对照组比较,肥胖组和抑制剂组干预8周体质量较基线体质量增加显著升高(P<0.01),血糖、胰岛素、TNF-α、白细胞介素6和丙二醛水平明显升高(P<0.05,P<0.01),胆红素、超氧化物歧化酶[(3.26±0.51)μg/L和(5.90±0.49)μg/L vs (8.66±0.70)μg/L,P<0.05,P<0.01]和脂联素水平明显降低[(4.16±0.75)μg/L和(4.62±0.52)μg/L vs (6.72±1.09)μg/L,P<0.05],诱导剂组上述指标无明显变化(P>0.05);肥胖组和抑制剂组左心室舒张末期内径、左心室收缩末期内径显著增大(P<0.01),左心室短轴缩短率和LVEF及左心室最大压力最大变化速率显著降低(P<0.05,P<0.01),肥胖组左心室收缩压和左心室舒张末压明显升高(P<0.01),而诱导剂组上述指标则无明显变化(P>0.05)。肥胖组和抑制剂组心肌组织HO-1和脂联素mRNA和蛋白表达较对照组明显减低(P<0.05,P<0.01);诱导剂组HO-1和脂联素蛋白表达显著高于肥胖组和抑制剂组(P<0.01);而抑制剂组与肥胖组HO-1和脂联素蛋白表达无显著差异(P>0.05)。苏木精-伊红染色显示,肥胖组心肌细胞肥大、充血,心肌细胞间有较明显的纤维条索形成,慢性炎性反应明显,抑制剂组心肌组织也有较明显的充血、心肌细胞肥大,纤维条索形成,但是较肥胖组减轻;诱导剂组与对照组相似。结论 L-4F上调肥胖大鼠HO-1与脂联素轴,降低肥胖大鼠体质量,减轻胰岛素抵抗和炎性反应,改善氧化应激状态,抑制心肌重构,改善肥胖大鼠的心功能。展开更多
目的：研究不同甲状腺功能状态对孕妇血清高密度脂蛋白胆固醇（high density cholesterol,HDL-C）和载脂蛋白A-Ⅰ（apolipoprotein A-Ⅰ,ApoA-Ⅰ）代谢的影响。方法：采集30名甲状腺功能正常（正常组）、19名亚临床甲状腺功能减退（亚...目的：研究不同甲状腺功能状态对孕妇血清高密度脂蛋白胆固醇（high density cholesterol,HDL-C）和载脂蛋白A-Ⅰ（apolipoprotein A-Ⅰ,ApoA-Ⅰ）代谢的影响。方法：采集30名甲状腺功能正常（正常组）、19名亚临床甲状腺功能减退（亚甲减组）及8名亚临床甲状腺功能亢进（亚甲亢组）孕妇孕9~12、14~17、23~26和37~40周的空腹血清标本,测其血清HDL-C和ApoA-Ⅰ含量。采用重复测量数据方差分析的秩和检验分析4个妊娠时段孕妇血清HDL-C、ApoA-Ⅰ含量的变化;采用一般线性模型（general linear model,GLM）分析3组孕妇孕期血清HDL-C、ApoA-Ⅰ含量的差异。结果：孕期各组孕妇血清HDL-C含量的变化差异均无统计学意义（χ~2=5.428,P=0.143;χ~2=2.027,P=0.567;χ~2=2.885,P=0.410）,正常孕妇和亚甲减孕妇血清ApoA-Ⅰ的含量增高,差异均有统计学意义（χ~2=46.343,P〈0.001;χ~2=35.984,P〈0.001）,亚甲亢孕妇血清ApoA-Ⅰ含量的变化差异无统计学意义（χ~2=6.750,P=0.080）。亚甲亢孕妇孕期血清HDL-C和ApoA-Ⅰ的含量均低于正常孕妇,差异均有统计学意义（P=0.025,P=0.027）,正常孕妇与亚甲减孕妇孕期血清HDL-C和ApoA-Ⅰ含量的差异均无统计学意义（P=0.378,P=0.549）。结论：妊娠期亚甲亢影响孕妇血清HDL-C和ApoA-Ⅰ代谢,进而影响胎儿的生长发育;妊娠期亚甲减（经优甲乐治疗后）未发现影响孕妇血清HDL-C和ApoA-Ⅰ代谢。展开更多
目的通过激动或抑制HepG2细胞的β3肾上腺素能受体(β3-AR),探讨β3-AR调节胆固醇逆转运过程的可能机制。方法将培养的HepG2细胞随机分为对照组、β3-AR激动剂组(激动剂组)和β3-AR拮抗剂组(拮抗剂组),ELISA法检测上清液载脂蛋白(apo)A...目的通过激动或抑制HepG2细胞的β3肾上腺素能受体(β3-AR),探讨β3-AR调节胆固醇逆转运过程的可能机制。方法将培养的HepG2细胞随机分为对照组、β3-AR激动剂组(激动剂组)和β3-AR拮抗剂组(拮抗剂组),ELISA法检测上清液载脂蛋白(apo)A-Ⅰ、apoA-Ⅱ及β3-AR水平;测定细胞内胆固醇、游离胆固醇和胆固醇酯水平,3 H标记的胆固醇测定胆固醇流出率,实时定量PCR和蛋白印迹法分别检测细胞中三磷酸腺苷结合盒转运蛋白A1(ABCA1)和肝X受体α亚型(LXRα)的表达。结果与对照组比较,激动剂组apoA-Ⅰ、游离胆固醇、胆固醇流出率显著增加,胆固醇、胆固醇酯显著降低,ABCA1和LXRαmRNA及ABCA1和LXRα蛋白显著增加;拮抗剂组胆固醇、胆固醇酯显著升高,apoA-Ⅰ、胆固醇流出率显著减少,ABCA1和LXRαmRNA及ABCA1和LXRα蛋白显著降低。与激动剂组比较,拮抗剂组ABCA1和LXRαmRNA及ABCA1和LXRα蛋白显著降低(0.49±0.10 vs1.24±0.02,0.85±0.05 vs 1.32±0.05,0.38±0.01 vs 1.45±0.20,0.08±0.01 vs 0.76±0.02,P<0.01)。结论激动HepG2细胞的β3-AR,可上调apoA-Ⅰ表达,促进巨噬细胞源性泡沫细胞胆固醇逆转运相关蛋白的表达。展开更多
Apolipoprotein A Ⅰ, the major protein component of the HDL, exerts its important function during modulating the metabolism of lipids in the plasma. Animal experiments have established that high concentration of the a...Apolipoprotein A Ⅰ, the major protein component of the HDL, exerts its important function during modulating the metabolism of lipids in the plasma. Animal experiments have established that high concentration of the apo A Ⅰ not only inhibits the initiation and progression of atherosclerosis, but also makes the preexisting atherosclerotic lesions regress. The most accepted mechanism is reverse cholesterol transport(RCT). It may become a new non traumatic therapy that the atherosclerosis is prevented and treated by the purified or recombinant human apolipoprotein A Ⅰ.展开更多
文摘To identify, clone ,sequence and highly express the mature peptide gene of ApoA Ⅰ, total RNA was prepared from human fetal liver tissue. cDNA fragment encoding human ApoA Ⅰ was amplified by RT-PCR using specific primers, and then was inserted in pGEM-T vector. DNA sequencing indicates that the fragment is 729 base pairs in length and has 100% nucleotide homology with that of reported ApoA Ⅰ cDNA gene previously. The ApoA Ⅰ gene was cloned into pGEX 5X-1.The recombinant protein was expressed in E.coli DH5α, purified by glutathione-Sepharose 4B affinity chromatography and confirmed by SDS-PAGE. It was shown that the recombinant ApoA Ⅰ was expressed in E.coli, and the target protein amounted to 36% of total bacteria proteins. Cholesteryl ester transfer experiment showed that the recombinant ApoA Ⅰ was capable of promoting transfer of CE from HDL to LDL. Western blotting showed that the protein could react specifically with anti-ApoA Ⅰ antibodies.
文摘目的探讨载脂蛋白A-Ⅰ模拟肽(L-4F)对肥胖大鼠心功能的影响及可能机制。方法 50只SD大鼠中,随机选择10只喂食普通饲料为对照组,另40只喂食高脂饲料8周后,肥胖模型造模成功率75%,将肥胖模型成功大鼠30只再随机分为肥胖组、诱导剂组[血红素氧合酶1(HO-1)诱导剂L-4F]和抑制剂组(HO-1抑制剂SnMP),每组10只,各组每天腹腔注射相应药物,持续8周。心脏超声和血流动力学检测后,自腹主动脉取血,ELISA检测各项指标。苏木精-伊红染色观察心肌组织病理变化;分别用RT-PCR和Western blot测心肌组织HO-1、脂联素基因和蛋白表达。结果与对照组比较,肥胖组和抑制剂组干预8周体质量较基线体质量增加显著升高(P<0.01),血糖、胰岛素、TNF-α、白细胞介素6和丙二醛水平明显升高(P<0.05,P<0.01),胆红素、超氧化物歧化酶[(3.26±0.51)μg/L和(5.90±0.49)μg/L vs (8.66±0.70)μg/L,P<0.05,P<0.01]和脂联素水平明显降低[(4.16±0.75)μg/L和(4.62±0.52)μg/L vs (6.72±1.09)μg/L,P<0.05],诱导剂组上述指标无明显变化(P>0.05);肥胖组和抑制剂组左心室舒张末期内径、左心室收缩末期内径显著增大(P<0.01),左心室短轴缩短率和LVEF及左心室最大压力最大变化速率显著降低(P<0.05,P<0.01),肥胖组左心室收缩压和左心室舒张末压明显升高(P<0.01),而诱导剂组上述指标则无明显变化(P>0.05)。肥胖组和抑制剂组心肌组织HO-1和脂联素mRNA和蛋白表达较对照组明显减低(P<0.05,P<0.01);诱导剂组HO-1和脂联素蛋白表达显著高于肥胖组和抑制剂组(P<0.01);而抑制剂组与肥胖组HO-1和脂联素蛋白表达无显著差异(P>0.05)。苏木精-伊红染色显示,肥胖组心肌细胞肥大、充血,心肌细胞间有较明显的纤维条索形成,慢性炎性反应明显,抑制剂组心肌组织也有较明显的充血、心肌细胞肥大,纤维条索形成,但是较肥胖组减轻;诱导剂组与对照组相似。结论 L-4F上调肥胖大鼠HO-1与脂联素轴,降低肥胖大鼠体质量,减轻胰岛素抵抗和炎性反应,改善氧化应激状态,抑制心肌重构,改善肥胖大鼠的心功能。
文摘目的：研究不同甲状腺功能状态对孕妇血清高密度脂蛋白胆固醇（high density cholesterol,HDL-C）和载脂蛋白A-Ⅰ（apolipoprotein A-Ⅰ,ApoA-Ⅰ）代谢的影响。方法：采集30名甲状腺功能正常（正常组）、19名亚临床甲状腺功能减退（亚甲减组）及8名亚临床甲状腺功能亢进（亚甲亢组）孕妇孕9~12、14~17、23~26和37~40周的空腹血清标本,测其血清HDL-C和ApoA-Ⅰ含量。采用重复测量数据方差分析的秩和检验分析4个妊娠时段孕妇血清HDL-C、ApoA-Ⅰ含量的变化;采用一般线性模型（general linear model,GLM）分析3组孕妇孕期血清HDL-C、ApoA-Ⅰ含量的差异。结果：孕期各组孕妇血清HDL-C含量的变化差异均无统计学意义（χ~2=5.428,P=0.143;χ~2=2.027,P=0.567;χ~2=2.885,P=0.410）,正常孕妇和亚甲减孕妇血清ApoA-Ⅰ的含量增高,差异均有统计学意义（χ~2=46.343,P〈0.001;χ~2=35.984,P〈0.001）,亚甲亢孕妇血清ApoA-Ⅰ含量的变化差异无统计学意义（χ~2=6.750,P=0.080）。亚甲亢孕妇孕期血清HDL-C和ApoA-Ⅰ的含量均低于正常孕妇,差异均有统计学意义（P=0.025,P=0.027）,正常孕妇与亚甲减孕妇孕期血清HDL-C和ApoA-Ⅰ含量的差异均无统计学意义（P=0.378,P=0.549）。结论：妊娠期亚甲亢影响孕妇血清HDL-C和ApoA-Ⅰ代谢,进而影响胎儿的生长发育;妊娠期亚甲减（经优甲乐治疗后）未发现影响孕妇血清HDL-C和ApoA-Ⅰ代谢。
文摘目的通过激动或抑制HepG2细胞的β3肾上腺素能受体(β3-AR),探讨β3-AR调节胆固醇逆转运过程的可能机制。方法将培养的HepG2细胞随机分为对照组、β3-AR激动剂组(激动剂组)和β3-AR拮抗剂组(拮抗剂组),ELISA法检测上清液载脂蛋白(apo)A-Ⅰ、apoA-Ⅱ及β3-AR水平;测定细胞内胆固醇、游离胆固醇和胆固醇酯水平,3 H标记的胆固醇测定胆固醇流出率,实时定量PCR和蛋白印迹法分别检测细胞中三磷酸腺苷结合盒转运蛋白A1(ABCA1)和肝X受体α亚型(LXRα)的表达。结果与对照组比较,激动剂组apoA-Ⅰ、游离胆固醇、胆固醇流出率显著增加,胆固醇、胆固醇酯显著降低,ABCA1和LXRαmRNA及ABCA1和LXRα蛋白显著增加;拮抗剂组胆固醇、胆固醇酯显著升高,apoA-Ⅰ、胆固醇流出率显著减少,ABCA1和LXRαmRNA及ABCA1和LXRα蛋白显著降低。与激动剂组比较,拮抗剂组ABCA1和LXRαmRNA及ABCA1和LXRα蛋白显著降低(0.49±0.10 vs1.24±0.02,0.85±0.05 vs 1.32±0.05,0.38±0.01 vs 1.45±0.20,0.08±0.01 vs 0.76±0.02,P<0.01)。结论激动HepG2细胞的β3-AR,可上调apoA-Ⅰ表达,促进巨噬细胞源性泡沫细胞胆固醇逆转运相关蛋白的表达。
文摘Apolipoprotein A Ⅰ, the major protein component of the HDL, exerts its important function during modulating the metabolism of lipids in the plasma. Animal experiments have established that high concentration of the apo A Ⅰ not only inhibits the initiation and progression of atherosclerosis, but also makes the preexisting atherosclerotic lesions regress. The most accepted mechanism is reverse cholesterol transport(RCT). It may become a new non traumatic therapy that the atherosclerosis is prevented and treated by the purified or recombinant human apolipoprotein A Ⅰ.
